{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:03:21Z","timestamp":1792839801470,"version":"4.5.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Outcomes of persons with chronic hepatitis B virus (HBV) infection in the era of antiviral therapy (AVT) are not well characterized. We determined the incidence and factors associated with clinical outcomes in a multiethnic, North American cohort of adults with chronic HBV infection, who were not on AVT at enrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results<\/jats:title>\n                    <jats:p>Adults with chronic HBV infection, not receiving AVT, and without a history of decompensation, HCC, or liver transplantation (LT), were prospectively followed. Participants with known human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D virus (HDV) coinfection were excluded. During follow\u2010up, treatment could be initiated per standard of care. Clinical outcomes included: incident cirrhosis, decompensation, HCC, OLT, and HBV\u2010related death. Among 1,418 participants analyzed, 51.5% were women, median age was 41.1\u00a0years, 75% were Asian, 10% White, 13% Black, 24% HBeAg(+), and 1.5% cirrhosis at baseline. During the study, 274 started treatment, 83 had an alanine aminotransferase flare, 118 of 330 initially HBeAg(+) became HBeAg(\u2212), and 90 of 1,329 became HBsAg(\u2212). After 6,641 person\u2010years follow\u2010up, 8 participants (4 of 21 with baseline cirrhosis) had 12 clinical outcomes (2 decompensation, 5 HCC, 2 OLT, and 3 HBV\u2010related deaths) and 19 of 1,397 had incident cirrhosis. Twenty\u2010one of 26 participants had first outcome before treatment, none had become HBsAg(\u2212), whereas 5\/9 HBeAg(+) had become HBeAg(\u2212) at time of first outcome. Cumulative percentage of clinical outcomes was 16% at year 4 in participants with baseline cirrhosis and 2% (including incident cirrhosis) at year 7 in those without.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Incidence of adverse outcomes was low in this closely monitored, large cohort of North American adults with predominantly inactive, chronic HBV without cirrhosis. Our data highlight the benefits of HBsAg loss and the importance of early diagnosis and treatment to prevent cirrhosis and other complications of chronic HBV infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.31554","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T19:16:57Z","timestamp":1600283817000},"page":"2124-2140","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":41,"title":["Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy"],"prefix":"10.1097","volume":"73","author":[{"given":"Anna S.","family":"Lok","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology,University of Michigan,Ann Arbor,MI,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perrillo","sequence":"additional","affiliation":[{"name":"Hepatology Division,Baylor Scott and White Medical Center,Dallas,TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Lalama","sequence":"additional","affiliation":[{"name":"Graduate School of Public Health,University of Pittsburgh,Pittsburgh,PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Fried","sequence":"additional","affiliation":[{"name":"UNC Liver Center,University of North Carolina at Chapel Hill,Chapel Hill,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Belle","sequence":"additional","affiliation":[{"name":"Epidemiology and Biostatistics,Graduate School of Public Health,University of Pittsburgh,Pittsburgh,PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2837-0188","authenticated-orcid":false,"given":"Marc G.","family":"Ghany","sequence":"additional","affiliation":[{"name":"Liver Diseases Branch,NIDDK,NIH,Bethesda,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Khalili","sequence":"additional","affiliation":[{"name":"Department of Medicine,Division of Gastroenterology and Hepatology,University of California San Francisco,San Francisco,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fontana","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,University of Michigan,Ann Arbor,MI,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Sterling","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition,Virginia Commonwealth University,Richmond,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4143-1950","authenticated-orcid":false,"given":"Norah","family":"Terrault","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal and Liver Diseases,Keck Medicine of University of Southern California,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease,University Health Network,University of Toronto,Toronto,ON,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6075-9305","authenticated-orcid":false,"given":"Adrian M.","family":"Di Bisceglie","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,Saint Louis University School of Medicine,St. Louis,MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4139-1987","authenticated-orcid":false,"given":"Daryl T.Y.","family":"Lau","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Beth Israel Deaconess Medical Center,Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hassan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition,University of Minnesota,Minneapolois,MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease,University of Toronto,Toronto,ON,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Hepatitis B Research Network (HBRN)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"hep31554-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.30831","article-title":"Chronic hepatitis B prevalence among foreign\u2010born and U.S.\u2010born adults in the United States, 1999\u20102016","volume":"71","year":"2020","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"hep31554-bib-0002-20250824","first-page":"100","article-title":"Natural history of chronic hepatitis B virus infection and long\u2010term outcome under treatment","volume":"29","year":"2009","journal-title":"Liver Int"},{"key":"hep31554-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1478-3231.2012.02805.x","article-title":"Natural history of chronic hepatitis B: what exactly has REVEAL revealed?","volume":"32","year":"2012","journal-title":"Liver Int"},{"key":"hep31554-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","year":"2008","journal-title":"J Hepatol"},{"key":"hep31554-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0168-8278(00)00094-5","article-title":"The long\u2010term outcome of interferon\u2010alpha treated and untreated patients with HBeAg\u2010negative chronic hepatitis B","volume":"34","year":"2001","journal-title":"J Hepatol"},{"key":"hep31554-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jnci\/dji043","article-title":"Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men","volume":"97","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"hep31554-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1136\/gutjnl-2015-309892","article-title":"Natural history of chronic HBV infection in West Africa: a longitudinal population\u2010based study from The Gambia","volume":"65","year":"2016","journal-title":"Gut"},{"key":"hep31554-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/liv.13129","article-title":"Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people","volume":"36","year":"2016","journal-title":"Liver Int"},{"issue":"5 Suppl.","key":"hep31554-bib-0009-20250824","first-page":"S45","article-title":"The natural history of chronic hepatitis B virus infection","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"hep31554-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/hep.22476","article-title":"Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States","volume":"48","year":"2008","journal-title":"Hepatology"},{"key":"hep31554-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jhep.2019.01.037","article-title":"The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"hep31554-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5\u2010year open\u2010label follow\u2010up study","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"hep31554-bib-0013-20250824","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep31554-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep31554-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study","volume":"147","year":"2014","journal-title":"Gastroenterology"},{"key":"hep31554-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four\u2010year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","year":"2016","journal-title":"Liver Int"},{"key":"hep31554-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2018.01.031","article-title":"Eight\u2010year survival in chronic hepatitis B patients under long\u2010term entecavir or tenofovir therapy is similar to the general population","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep31554-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cgh.2013.09.062","article-title":"Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population","volume":"12","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31554-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian\u2010Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","year":"2016","journal-title":"Hepatol Int"},{"key":"hep31554-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep31554-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep31554-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cgh.2014.06.028","article-title":"Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31554-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.30417","article-title":"Entecavir and peginterferon alfa\u20102a in adults with hepatitis B e antigen\u2010positive immune\u2010tolerant chronic hepatitis B virus infection","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep31554-bib-0025-20250824","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/JCM.00813-10","article-title":"Robust hepatitis B virus genotyping by mass spectrometry","volume":"48","year":"2010","journal-title":"J Clin Microbiol"},{"key":"hep31554-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jvh.12643","article-title":"Determination of hepatitis B phenotype using biochemical and serological markers","volume":"24","year":"2017","journal-title":"J Viral Hepat"},{"key":"hep31554-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","year":"2003","journal-title":"Hepatology"},{"key":"hep31554-bib-0028-20250824","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep31554-bib-0029-20250824","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/oxfordjournals.aje.a009060","article-title":"Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers","volume":"145","year":"1997","journal-title":"Am J Epidemiol"},{"key":"hep31554-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","year":"2006","journal-title":"JAMA"},{"key":"hep31554-bib-0031-20250824","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","year":"2006","journal-title":"Gastroenterology"},{"key":"hep31554-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","article-title":"Risk and predictors of mortality associated with chronic hepatitis B infection","volume":"5","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31554-bib-0033-20250824","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"hep31554-bib-0034-20250824","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cncr.30246","article-title":"Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States","volume":"123","year":"2017","journal-title":"Cancer"},{"key":"hep31554-bib-0035-20250824","article-title":"Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"hep31554-bib-0036-20250824","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/liv.13705","article-title":"Serum alanine aminotransferase level and liver\u2010related mortality in patients with chronic hepatitis B: a large national cohort study","volume":"38","year":"2018","journal-title":"Liver Int"},{"key":"hep31554-bib-0037-20250824","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apt.15311","article-title":"High risk of clinical events in untreated HBeAg\u2010negative chronic hepatitis B patients with high viral load and no significant ALT elevation","volume":"50","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"hep31554-bib-0038-20250824","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long\u2010term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","year":"2002","journal-title":"Hepatology"},{"key":"hep31554-bib-0039-20250824","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","year":"2014","journal-title":"Gut"},{"key":"hep31554-bib-0040-20250824","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/gutjnl-2013-305785","article-title":"Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma","volume":"63","year":"2014","journal-title":"Gut"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31554","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:05:14Z","timestamp":1756080314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31554","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"2020-06-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}